跳至主要内容
临床试验/NCT00261222
NCT00261222已完成2 期

Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso

Heidelberg University2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2005年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
120
试验地点
2
主要终点
Total clinical failure rate on day 14.

研究概览

简要总结

Design: Single-centre

Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the rural and the urban study area of the Centre de Recherche en Santé de Nouna (CRSN).

Population: Children aged 6-59 months with uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C + ≥ 2.000 P. falciparum asexual parasites per µl blood) from the health centre situated in the villages of Bagala, Bourasso and Kemena and from Nouna town hospital outpatient department.

Sample size: N=120

Treatment: All children will receive a total dose of 25 mg/kg oral AQ over a period of three days (first and second day: 10mg/kg, third day: 5mg/kg).

Statistical procedures: The primary analysis parameter is the proportion of clinical failures on day 14. Secondary parameters are the rate of clinical failures on day 28 (with and without PCR correction), the rate of early clinical failures, the rate of late parasitological failures (day 14 and day 28), and the rate of adverse events. Data will be analysed in the overall group of study children and for rural (n=50) and urban (n=50) study children separately.

Study duration and dates: The study will be implemented in September-December 2005.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 59 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Age 6-59 months
  • Uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C and ≥ 2.000 P. falciparum asexual parasites per µl blood)
  • Written informed consent given by the parents/caretakers

排除标准

  • Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin < 7 g/dl or haematocrit < 21%)
  • Any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)
  • Malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine.

结局指标

主要结局

Total clinical failure rate on day 14.

Clinical failure rate on day 14 in rural study area.

Clinical failure rate on day 14 in urban study area.

次要结局

  • Total early clinical failure rate.
  • Total clinical failure rate on day 28.
  • Clinical failure rate on day 28 in rural study area.
  • Clinical failure rate on day 28 in urban study area.
  • Early clinical failure rate in rural study area.
  • Early clinical failure rate in urban study area.
  • Total late parasitological failure rate on day 14 and 28.
  • Late parasitological failure rate on day 14 and 28 in rural study area.
  • Late parasitological failure rate on day 14 and 28 in urban study area.
  • Incidence of observed and self-reported adverse events over the 28 days observation period
  • Monitoring of concomitant drug intake

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验